CURC has recently shown anti-tumor properties, relying on the inhibition of oncogenic/pro-survival STAT-3 and NF-kB-dependent pathways, of the pro-invasive factor Sp-1, of tumor-associated inflammation [51,52]. Here, STAT3 is linked to neoplasm.